A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia

Table 3

Cases of acquired haemophilia A with chronic myelomonocytic leukaemia or myelodysplastic syndromes.

No	Age/gender	Disease	Clinical manifestation	APTT (second)	FVIII activity (%)	FVIII inhibitor titer (BU/ml)	Treatment for bleeding and antibody eradication	Anti-tumor agent	Outcome of AHA	Reference
1	54/M	CMML-1	Large ecchymosis at trunk and extremities	73.4	No data	21	PSL	Azacitidine, panobinostat	CR	[11]
2	41/M	CMML-2	Excessive bleeding	91	No data	107.5	CPA, PSL		Non-CR	[11]
3	58/M	CMML-1	Diffuse ecchymosis and spontaneous iliopsoas hematoma	96.3	<1	>200	APCC, PSL, CPA, rituximab, IVIG	Decitabine	CR	[12]
4	71/M	CMML-1	Gross hematuria	118.6	6.7	7.4	HU, rFVIII	Decitabine, CAG regimen	CR	[13]
5	75/F	MDS	Extensive bruising on body and limbs	71	2	420	PSL, pyridoxine		CR	[14]
6	84/M	MDS (RAEB-1)	Subcutaneous and muscle bleeding	71.8	3	3	rFVIIa, PSL		Non-CR	[15]
7	71/M	MDS/MPN	Spontaneous hematoma and muscle hemorrhage	64	24	9	rFVIII, rFVIIa, APCC, PSL, CPA, IVIG		Non-CR	[16]
8	67/M	CMML-0	Subcutaneous and muscle bleeding	85.8	<1	166	APCC, PSL, CyA, CPA, AZP	Azacitidine	Non-CR	Our case

M: male; F: female; CMML: chronic myelomonocytic leukaemia; MDS: myelodysplastic syndromes; PSL: prednisolone; CyA: cyclosporine A; CPA: cyclophosphamide; AZP: azathioprine; HU: hydroxyurea; IVIG: intravenous immunoglobulin; rFVIIa: recombinant factor VIIa; rFVIII: recombinant factor VIII; APCC: activated prothrombin complex concentrate; CR: complete remission; Ref: reference. Diagnosed by WHO 2016 classification.